Limits...
Intraductal Radiofrequency Ablation Followed by Locoregional Tumor Treatments for Treating Occluded Biliary Stents in Non-Resectable Malignant Biliary Obstruction: A Single-Institution Experience.

Duan XH, Wang YL, Han XW, Ren JZ, Li TF, Zhang JH, Zhang K, Chen PF - PLoS ONE (2015)

Bottom Line: The practicality, safety, postoperative complications, jaundice remission, stent patency and survival time were analyzed.Combination treatment was successful for all patients.Intraductal RFA followed by locoregional tumor treatments for occluded metal stents is safe and practically feasible and potential increase stent patency and survival times.

View Article: PubMed Central - PubMed

Affiliation: Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, No. 1, East Jian She Road, Zhengzhou, 450052, Henan Province, People's Republic of China.

ABSTRACT

Objectives: To determine the safety and feasibility of intraductal radiofrequency ablation (RFA) followed by locoregional tumor treatments in patients with non-resectable malignant biliary obstruction and stent re-occlusion.

Methods: Fourteen patients with malignant biliary obstruction and blocked metal stents were studied retrospectively. All had intraductal RFA followed by locoregional tumor treatments and were monitored clinically and radiologically. The practicality, safety, postoperative complications, jaundice remission, stent patency and survival time were analyzed.

Results: Combination treatment was successful for all patients. There were no severe complications during RFA or local treatments. All patients had stent patency restored, with a decline in serum bilirubin. Three patients had recurrent jaundice by 195, 237 and 357 days; two patients underwent repeat intraductal RFA; and one required an internal-external biliary drain. The average stent patency time was 234 days (range 187-544 days). With a median follow-up of 384 days (range 187-544 days), six patients were alive, while eight had died. There was no mortality at 30 days. The 3, 6, 12 and 18 month survival rates were 100%, 100%, 64.3% and 42.9%, respectively.

Conclusion: Intraductal RFA followed by locoregional tumor treatments for occluded metal stents is safe and practically feasible and potential increase stent patency and survival times.

No MeSH data available.


Related in: MedlinePlus

Survival curve for the intraductal RFA followed by locoregional tumor treatments as treatment for occluded biliary stents in malignant biliary obstruction.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526692&req=5

pone.0134857.g003: Survival curve for the intraductal RFA followed by locoregional tumor treatments as treatment for occluded biliary stents in malignant biliary obstruction.

Mentions: Fig 3 shows the Kaplan-Meier curves depicting survival trends. Of the fourteen patients, six are alive and eight patients have died, at a median follow-up of 384 days (range 187–544 days). The 3, 6, 12, and 18 month survival rates were 100% (14/14), 100% (14/14), 64.3% (9/14) and 42.9% (6/14), respectively. One patient with CCA Bismuth IV with liver metastases died at 187 days, and one patient with HCC died 234 days after the procedure due to liver failure. The remaining six patients died of disease progression. Stent patency was preserved even in those patients who died.


Intraductal Radiofrequency Ablation Followed by Locoregional Tumor Treatments for Treating Occluded Biliary Stents in Non-Resectable Malignant Biliary Obstruction: A Single-Institution Experience.

Duan XH, Wang YL, Han XW, Ren JZ, Li TF, Zhang JH, Zhang K, Chen PF - PLoS ONE (2015)

Survival curve for the intraductal RFA followed by locoregional tumor treatments as treatment for occluded biliary stents in malignant biliary obstruction.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526692&req=5

pone.0134857.g003: Survival curve for the intraductal RFA followed by locoregional tumor treatments as treatment for occluded biliary stents in malignant biliary obstruction.
Mentions: Fig 3 shows the Kaplan-Meier curves depicting survival trends. Of the fourteen patients, six are alive and eight patients have died, at a median follow-up of 384 days (range 187–544 days). The 3, 6, 12, and 18 month survival rates were 100% (14/14), 100% (14/14), 64.3% (9/14) and 42.9% (6/14), respectively. One patient with CCA Bismuth IV with liver metastases died at 187 days, and one patient with HCC died 234 days after the procedure due to liver failure. The remaining six patients died of disease progression. Stent patency was preserved even in those patients who died.

Bottom Line: The practicality, safety, postoperative complications, jaundice remission, stent patency and survival time were analyzed.Combination treatment was successful for all patients.Intraductal RFA followed by locoregional tumor treatments for occluded metal stents is safe and practically feasible and potential increase stent patency and survival times.

View Article: PubMed Central - PubMed

Affiliation: Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, No. 1, East Jian She Road, Zhengzhou, 450052, Henan Province, People's Republic of China.

ABSTRACT

Objectives: To determine the safety and feasibility of intraductal radiofrequency ablation (RFA) followed by locoregional tumor treatments in patients with non-resectable malignant biliary obstruction and stent re-occlusion.

Methods: Fourteen patients with malignant biliary obstruction and blocked metal stents were studied retrospectively. All had intraductal RFA followed by locoregional tumor treatments and were monitored clinically and radiologically. The practicality, safety, postoperative complications, jaundice remission, stent patency and survival time were analyzed.

Results: Combination treatment was successful for all patients. There were no severe complications during RFA or local treatments. All patients had stent patency restored, with a decline in serum bilirubin. Three patients had recurrent jaundice by 195, 237 and 357 days; two patients underwent repeat intraductal RFA; and one required an internal-external biliary drain. The average stent patency time was 234 days (range 187-544 days). With a median follow-up of 384 days (range 187-544 days), six patients were alive, while eight had died. There was no mortality at 30 days. The 3, 6, 12 and 18 month survival rates were 100%, 100%, 64.3% and 42.9%, respectively.

Conclusion: Intraductal RFA followed by locoregional tumor treatments for occluded metal stents is safe and practically feasible and potential increase stent patency and survival times.

No MeSH data available.


Related in: MedlinePlus